Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887465 | 0.88 | AR (0.50) | ARPLA2G2AMEN1KMT2APOLB | |
| SCHEMBL4893680 | 0.87 | AR (0.60) | ARPLA2G2AMEN1KMT2AELANE | |
| SCHEMBL4893850 | 0.86 | PLA2G2A (0.46) | PLA2G2AKMT2APOLBMAPTKDM4E | |
| SCHEMBL4884093 | 0.85 | AR (0.58) | ARPLA2G2AMEN1KMT2AELANE | |
| SCHEMBL4891631 | 0.83 | AR (0.56) | ARPLA2G2AMEN1KMT2APOLB | |
| SCHEMBL4892207 | 0.79 | PLA2G2A (0.58) | ARPLA2G2AMEN1KMT2APOLB | |
| SCHEMBL5428229 | 0.77 | AR (0.61) | ARPLA2G2AMEN1KMT2APOLB | |
| SCHEMBL6858317 | 0.74 | ELANE (0.51) | ARPLA2G2AKMT2AELANEMAPT | |
| SCHEMBL4893855 | 0.74 | HRH3 (0.48) | PLA2G2AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL4893267 | 0.74 | MAPT (0.69) | ARMEN1KMT2AELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7442805-B2 | Substituted sulfonamide-indoles | WYETH (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050096377-A1 | Substituted sulfonamide-indoles | WYETH (US) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | STS, TPST2, IDO2 | AR 877/4885PLA2G2A 3606/4885MEN1 3530/4885 |
| US-20050096377-A1 | Substituted sulfonamide-indoles | STS, TPST2, IDO2 | AR 877/4885PLA2G2A 3606/4885MEN1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.